Skip to main content
Sign In

Department of Pharmacology Faculty Members


Vikhyat Bebarta
M.D., 1998, George Washington University School of Medicine and Health Sciences

Associate Professor
M.D., 1989, Ohio State University College of Medicine

Innovative new treatments for ovarian cancers. 

Timothy A. Benke
Associate Professor
M.D./Ph.D., 1995, Baylor College of Medicine

Mechanisms of synaptic plasticity and impacts of development and epilepsy.

Patricia Ernst
Ph.D., 1996, Uni. of California, Los Angeles
Hematopoietic Stem Cell Development and Maintenance: The Role of the "Mixed Lineage Leukemia" Gene in Normal Blood Cell Development, Differentiation and Leukemia.

Paco Herson
Associate Professor
Ph.D., 1999, Univ. of Aberdeen, UK

Basic translational research using neurophysiology, biochemistry, molecular biology, histology and neuro-behavior to elucidate the mechanisms of neuronal injury and identify therapeutic targets for protection and repair.​


Vesna Jevtovic-Todorovic​
Professor and Chair, Anesthesiology 

Mechanisms by which anesthetic drugs interact with neurotransmitter systems in the central nervous system to produce pharmacological and toxicological effects.​

Jean Mulcahy Levy
Assistant Professor
MD, Oregon Health & Science University School of Medicine (2003)

My clinical interests focus on the care of children with tumors involving the brain and spinal cord, using a combination of therapies and coordinating services including surgery, radiation, and chemotherapy to improve outcomes for these patients.


Timothy McKinsey
Associate Professor and Associate Division Head for Translational Research 

J. David Port
Ph.D., 1989, Univ. of Utah

G-protein linked receptors and their regulation; regulation of mRNA stability.

Dan Theodorescu
Professor and Director of the Univ. of Colorado Comprehensive Cancer Center
M.D., 1986, Queen's Univ. Faculty of Health Sciences; Ph.D., 1993, Univ. of Toronto
I'm a physician scientist. Our translational molecular biology laboratory focuses on identifying the molecular mechanisms leading to bladder cancer metastasis and their potential applications to patients with this disease. Our group is at the forefront of the development of biomarkers and therapeutics in bladder cancer. My clinical practice is limited to bladder cancer management including surgery such as radical cystectomy using state of the art robotic techniques (i.e. da Vinci).